title: EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
abstract: EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, CMU, Taipei, Taiwan.
authors.forename: Ming-Jer
authors.initials: MJ
authors.lastname: Huang
authors.forename: Ken-Hong
authors.initials: KH
authors.lastname: Lim
authors.forename: Chin-Yuan
authors.initials: CY
authors.lastname: Tzen
authors.forename: Han-Shui
authors.initials: HS
authors.lastname: Hsu
authors.forename: Yun
authors.initials: Y
authors.lastname: Yen
authors.forename: Biing-Shiun
authors.initials: BS
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D000077156:Gefitinib; D017353:Gene Deletion; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016066:Pleural Effusion, Malignant / Q000235:genetics*; D016133:Polymerase Chain Reaction; D049268:Positron-Emission Tomography; D011799:Quinazolines / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib